Journal of the American Academy of Dermatology · 2020 · 126 citations · 28 references
MedicineDermatologyPharmacologyImmunopharmacologyImmunopharmacotherapyPediatric DermatologyAllergic Skin DiseasesAllergy PharmacotherapyAtopic DermatitisInflammatory Skin DisordersPruritus ManagementAtopic Dermatitis ItchAtopic Dermatitis PharmacotherapyAtopic Dermatitis TreatmentDupilumab ResponsePediatric Atopic DermatitisRandomized Clinical TrialsRandomized Crossover TrialsTreatment With Topical Corticosteroids
BackgroundPruritus (itch) is a cardinal symptom in atopic dermatitis (AD).ObjectiveTo evaluate the timing and effect of dupilumab on itch.MethodsAnalysis of data from 1505 patients with moderate to severe AD included in 4 randomized controlled studies, treated for up to 52 weeks. Adults received dupilumab 300 mg every 2 weeks or placebo monotherapy (SOLO 1: NCT02277743; SOLO 2: NCT02277769), with concomitant topical corticosteroids (CHRONOS: NCT02260986); adolescents (≥12 to <18 y) were treated with dupilumab monotherapy every 2 weeks (200 mg for baseline weight of <60 kg; 300 mg for baseline weight of ≥60 kg) or placebo (AD ADOL: NCT03054428).ResultsDupilumab showed significant rapid improvements from baseline in daily Peak Pruritus Numerical Rating Scale scores versus placebo, by day 2 in adults and day 5 in adolescents. At treatment end, dupilumab vs placebo/control had greater least-squares mean percent change from baseline in the weekly average of Peak Pruritus Numerical Rating Scale scores: SOLO −47.5% vs −20.5%; AD-ADOL −47.9% vs −19.0%; CHRONOS −57.3% vs −30.9% (P < .0001 for all).LimitationsShort duration of monotherapy trials (16 weeks).ConclusionAcross 4 randomized trials, dupilumab treatment showed rapid and sustained improvements in the magnitude of itch, starting with first dose; responses progressively increased and were sustained through to the end of treatment, up to 1 year. Pruritus (itch) is a cardinal symptom in atopic dermatitis (AD). To evaluate the timing and effect of dupilumab on itch. Analysis of data from 1505 patients with moderate to severe AD included in 4 randomized controlled studies, treated for up to 52 weeks. Adults received dupilumab 300 mg every 2 weeks or placebo monotherapy (SOLO 1: NCT02277743; SOLO 2: NCT02277769), with concomitant topical corticosteroids (CHRONOS: NCT02260986); adolescents (≥12 to <18 y) were treated with dupilumab monotherapy every 2 weeks (200 mg for baseline weight of <60 kg; 300 mg for baseline weight of ≥60 kg) or placebo (AD ADOL: NCT03054428). Dupilumab showed significant rapid improvements from baseline in daily Peak Pruritus Numerical Rating Scale scores versus placebo, by day 2 in adults and day 5 in adolescents. At treatment end, dupilumab vs placebo/control had greater least-squares mean percent change from baseline in the weekly average of Peak Pruritus Numerical Rating Scale scores: SOLO −47.5% vs −20.5%; AD-ADOL −47.9% vs −19.0%; CHRONOS −57.3% vs −30.9% (P < .0001 for all). Short duration of monotherapy trials (16 weeks). Across 4 randomized trials, dupilumab treatment showed rapid and sustained improvements in the magnitude of itch, starting with first dose; responses progressively increased and were sustained through to the end of treatment, up to 1 year.
28
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky et al. · New England Journal of Medicine · 2016 · 2K citations · Full text
Medicine, Dermatology, Immunology +12
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck, Diamant Thaçi, Jennifer D. Hamilton et al. · New England Journal of Medicine · 2014 · 1.4K citations
Medicine, Dermatology, Immunology +13
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text
Medicine, Dermatology, Immunology +17
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Landon K. Oetjen, Madison R. Mack, Jing Feng et al. · Cell · 2017 · 1.1K citations · Full text